JP2022537824A5 - - Google Patents
Info
- Publication number
- JP2022537824A5 JP2022537824A5 JP2021576275A JP2021576275A JP2022537824A5 JP 2022537824 A5 JP2022537824 A5 JP 2022537824A5 JP 2021576275 A JP2021576275 A JP 2021576275A JP 2021576275 A JP2021576275 A JP 2021576275A JP 2022537824 A5 JP2022537824 A5 JP 2022537824A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- receptor
- amino acid
- cancer
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025040192A JP2025106277A (ja) | 2019-06-26 | 2025-03-13 | Ｃｄ３抗原結合断片およびそれを含む組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866746P | 2019-06-26 | 2019-06-26 | |
| US62/866,746 | 2019-06-26 | ||
| US202063041059P | 2020-06-18 | 2020-06-18 | |
| US63/041,059 | 2020-06-18 | ||
| PCT/US2020/039673 WO2020264200A1 (en) | 2019-06-26 | 2020-06-25 | Cd3 antigen binding fragments and compositions comprising same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025040192A Division JP2025106277A (ja) | 2019-06-26 | 2025-03-13 | Ｃｄ３抗原結合断片およびそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537824A JP2022537824A (ja) | 2022-08-30 |
| JP2022537824A5 true JP2022537824A5 (https=) | 2023-06-30 |
| JP7651481B2 JP7651481B2 (ja) | 2025-03-26 |
Family
ID=74059962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576275A Active JP7651481B2 (ja) | 2019-06-26 | 2020-06-25 | Ｃｄ３抗原結合断片およびそれを含む組成物 |
| JP2025040192A Pending JP2025106277A (ja) | 2019-06-26 | 2025-03-13 | Ｃｄ３抗原結合断片およびそれを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025040192A Pending JP2025106277A (ja) | 2019-06-26 | 2025-03-13 | Ｃｄ３抗原結合断片およびそれを含む組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20230121775A1 (https=) |
| EP (1) | EP3990497A4 (https=) |
| JP (2) | JP7651481B2 (https=) |
| KR (1) | KR20220038068A (https=) |
| CN (1) | CN115175933A (https=) |
| AU (1) | AU2020308868A1 (https=) |
| BR (1) | BR112021026089A2 (https=) |
| CA (1) | CA3143519A1 (https=) |
| CL (1) | CL2021003448A1 (https=) |
| CO (1) | CO2022000406A2 (https=) |
| CR (1) | CR20210628A (https=) |
| DO (1) | DOP2021000264A (https=) |
| EC (1) | ECSP22005986A (https=) |
| IL (1) | IL289102A (https=) |
| MX (1) | MX2021015880A (https=) |
| PE (1) | PE20220600A1 (https=) |
| PH (1) | PH12021500051A1 (https=) |
| WO (1) | WO2020264200A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| AU2018393111B2 (en) * | 2017-12-21 | 2025-07-10 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| CA3143519A1 (en) * | 2019-06-26 | 2020-12-30 | Volker Schellenberger | Cd3 antigen binding fragments and compositions comprising same |
| MX2023013382A (es) | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| KR20230041711A (ko) | 2020-06-25 | 2023-03-24 | 아뮤닉스 파마슈티컬스, 인크. | Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법 |
| EP4631977A3 (en) | 2020-08-11 | 2025-12-10 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| WO2022040444A1 (en) * | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| US20240254241A1 (en) * | 2021-05-11 | 2024-08-01 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| WO2023092099A1 (en) * | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
| WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| KR20250133776A (ko) | 2023-02-10 | 2025-09-08 | 아뮤닉스 파마슈티컬스, 인크. | 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법 |
| CN121949565A (zh) | 2023-04-17 | 2026-05-01 | 阿穆尼克斯制药公司 | 靶向表皮生长因子受体的组合物及其制备和使用方法 |
| WO2024220870A1 (en) * | 2023-04-19 | 2024-10-24 | The University Of Chicago | Antibody-targeted enzymatic chemoprotection |
| WO2025122957A1 (en) | 2023-12-08 | 2025-06-12 | Amunix Pharmaceuticals, Inc. | Protease activatable cytokines and methods for making and using the same |
| CN120230203A (zh) * | 2023-12-28 | 2025-07-01 | 四川思柏沃生物技术有限公司 | 抗cd3抗体及其用途 |
| WO2025220804A1 (ko) * | 2024-04-18 | 2025-10-23 | 주식회사 큐로셀 | Cd5에 대한 신규 항체 및 이의 용도 |
| WO2026024863A2 (en) | 2024-07-24 | 2026-01-29 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| RU2016132863A (ru) * | 2014-01-15 | 2018-02-20 | Займворкс Инк. | БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| AU2018393111B2 (en) * | 2017-12-21 | 2025-07-10 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
| CA3143519A1 (en) * | 2019-06-26 | 2020-12-30 | Volker Schellenberger | Cd3 antigen binding fragments and compositions comprising same |
| JP7725466B2 (ja) * | 2019-11-13 | 2025-08-19 | アムニクス ファーマシューティカルズ， インコーポレイテッド | バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法 |
-
2020
- 2020-06-25 CA CA3143519A patent/CA3143519A1/en active Pending
- 2020-06-25 AU AU2020308868A patent/AU2020308868A1/en active Pending
- 2020-06-25 MX MX2021015880A patent/MX2021015880A/es unknown
- 2020-06-25 EP EP20833432.6A patent/EP3990497A4/en active Pending
- 2020-06-25 BR BR112021026089A patent/BR112021026089A2/pt unknown
- 2020-06-25 JP JP2021576275A patent/JP7651481B2/ja active Active
- 2020-06-25 US US17/621,993 patent/US20230121775A1/en active Pending
- 2020-06-25 PE PE2021002228A patent/PE20220600A1/es unknown
- 2020-06-25 KR KR1020227002573A patent/KR20220038068A/ko active Pending
- 2020-06-25 CN CN202080061316.5A patent/CN115175933A/zh active Pending
- 2020-06-25 PH PH1/2021/500051A patent/PH12021500051A1/en unknown
- 2020-06-25 WO PCT/US2020/039673 patent/WO2020264200A1/en not_active Ceased
- 2020-06-25 CR CR20210628A patent/CR20210628A/es unknown
- 2020-08-19 US US16/996,899 patent/US20210054077A1/en not_active Abandoned
-
2021
- 2021-12-15 DO DO2021000264A patent/DOP2021000264A/es unknown
- 2021-12-19 IL IL289102A patent/IL289102A/en unknown
- 2021-12-22 CL CL2021003448A patent/CL2021003448A1/es unknown
-
2022
- 2022-01-19 CO CONC2022/0000406A patent/CO2022000406A2/es unknown
- 2022-01-25 EC ECSENADI20225986A patent/ECSP22005986A/es unknown
-
2025
- 2025-03-13 JP JP2025040192A patent/JP2025106277A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537824A5 (https=) | ||
| US11253547B2 (en) | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| TWI890655B (zh) | 改良之抗原結合受體 | |
| US20240043535A1 (en) | IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES | |
| CN115023444A (zh) | 新型il2激动剂及其使用方法 | |
| US12522638B2 (en) | IL12 receptor agonists and methods of use thereof | |
| CN112638950B (zh) | 一种双特异性抗体 | |
| WO2023045977A1 (zh) | 白介素2突变体以及其融合蛋白 | |
| KR20180057720A (ko) | 다가 Fv 항체 | |
| JP2023512452A (ja) | Ｂｃｍａ指向性細胞免疫療法組成物および方法 | |
| CN117836328A (zh) | 一种多特异性抗原结合蛋白及其应用 | |
| JP2022553292A5 (https=) | ||
| JP2024537096A (ja) | がんの治療のための代替的なＰＤ１－ＩＬ７ｖイムノコンジュゲート | |
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| US20250333464A1 (en) | Il10 agonists and methods of use thereof | |
| US20250115657A1 (en) | Bispecific FC Fusion Proteins with sPD-1 and IL-15 | |
| CN120826234A (zh) | 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法 | |
| JP2025539875A (ja) | 融合ポリペプチドおよびその使用 | |
| RU2022101308A (ru) | Антигенсвязывающие фрагменты для cd3 и композиции, содержащие их | |
| TWI914333B (zh) | 一種雙特異性融合蛋白及其應用 | |
| WO2024199458A1 (en) | Il-2 variants with improved stability and compositions thereof | |
| US20240270836A1 (en) | Il12 receptor agonists and methods of use thereof | |
| CN118726265A (zh) | 自分泌多特异性纳米抗体的工程化免疫细胞 | |
| WO2025064716A1 (en) | T-cell modulatory polypeptides and methods of use thereof |